AEHR TEST SYSTEMS AND SUBSIDIARIES | |||||||||||
Reconciliation of GAAP to Non-GAAP Results | |||||||||||
(in thousands, except per share data) | |||||||||||
(unaudited) | |||||||||||
Three Months Ended | |||||||||||
Aug 31, | May 31, | Aug 31, | |||||||||
2020 | 2020 | 2019 | |||||||||
GAAP net income (loss) | $ | 107 | $ | (2,885 | ) | $ | (413 | ) | |||
Stock-based compensation expense | 270 | 300 | 199 | ||||||||
Restructuring | - | 220 | - | ||||||||
Dissolution of Aehr Test Systems Japan | (2,401 | ) | - | - | |||||||
Excess and obsolescence provision | - | 1,645 | - | ||||||||
Non-GAAP net loss | $ | (2,024 | ) | $ | (720 | ) | $ | (214 | ) | ||
GAAP net income (loss) per diluted share | $ | 0.00 | $ | (0.13 | ) | $ | (0.02 | ) | |||
Non-GAAP net loss per diluted share | $ | (0.09 | ) | $ | (0.03 | ) | $ | (0.01 | ) | ||
Shares used in GAAP diluted shares calculation | 23,455 | 23,060 | 22,708 | ||||||||
Shares used in non-GAAP diluted shares calculation | 23,248 | 23,060 | 22,708 | ||||||||
Non-GAAP net loss is a non-GAAP measure and should not be considered a replacement for GAAP results. Non-GAAP net loss is a financial measure the Company uses to evaluate the underlying results and operating performance of the business. The limitation of this measure is that it excludes items that impact the Company's current period net income. This limitation is best addressed by using this measure in combination with net income (loss) (the most directly comparable GAAP financial measure). These measures are not in accordance with GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies.
We believe these measures enhance investors ability to review the companys business from the same perspective as the Companys management and facilitate comparisons of this periods results with prior periods. |